Policy – Talk Bio

Ex-FDA Leaders Launch Canal Row Advisors, Offer Insights on Agency’s Challenges and Direction

1 week ago talkbio0Tagged Biological Science Disciplines, Canal Row Advisors, innovation, Leadership, Michael Rogers, Policy, public health medicine (field), reform, regulatory consulting, regulatory strategy, United States Food and Drug Administration

Canal Row Advisors; FDA leadership; regulatory consulting; Michael Rogers; Hilary Marston; life sciences; regulatory strategy; public health; FDA reform; innovation policy

A Concerning Pattern: Pharma Mulls UK Divestments as Government Action Lags in Life Sciences

1 month ago talkbio0Tagged AstraZeneca, Biological Science Disciplines, drug price, drug spending, eli lilly, Government, Investments, Merck, Nance-Horan syndrome, pharmaceutical divestment, Policy, R&D, sanofi, UK

UK life sciences; pharmaceutical divestment; Merck; AstraZeneca; Sanofi; Eli Lilly; R&D investment; drug pricing; government policy; NHS drug spending

RFK Jr. Blasts Pharma Industry and Spreads mRNA Vaccine Misinformation During Heated Senate Hearing

2 months ago talkbio0Tagged Centers for Disease Control and Prevention (U.S.), COVID19 (disease), Leadership, mRNA misinformation, Pharma Industry, Policy, public health medicine (field), RFK Jr., Senate hearing, Vaccines

RFK Jr.; Senate hearing; pharma industry; mRNA misinformation; COVID-19 vaccines; public health; vaccine policy; CDC leadership

RFK Jr. Faces Bipartisan Senate Criticism After CDC Shakeup

2 months ago talkbio0Tagged bipartisan criticism, Centers for Disease Control and Prevention (U.S.), director firing, Policy, public health medicine (field), RFK Jr., Senate hearing, Shakeup, Trump administration reforms, Vaccines

RFK Jr.; CDC shakeup; bipartisan criticism; Senate hearing; public health; vaccine policy; CDC director firing; Trump administration reforms

Paul Offit, RFK Jr. Critic, Removed from Key FDA Vaccine Panel

2 months ago talkbio0Tagged Advisory Committees, CHARGE Syndrome, Paul Offit, Policy, removal technique, RFK Jr., United States Food and Drug Administration, vaccine panel, Vaccines, VRBPAC

Paul Offit; FDA; vaccine panel; RFK Jr.; removal; vaccine policy; VRBPAC; advisory committee; HHS

Vinay Prasad Explains FDA’s Revocation of Pfizer’s Covid Vaccine EUA for Children

2 months ago talkbio0Tagged Child, COVID19 (disease), Emergency Situation, Emergency Use Authorization, EUA, Pfizer, Policy, Prasad, risk-benefit analysis, United States Food and Drug Administration, Vaccines

FDA; Pfizer; COVID-19 vaccine; emergency use authorization (EUA); children; Vinay Prasad; vaccine policy; risk-benefit analysis

Sanofi Contributes to Report Emphasizing Importance of Sustainably Paid Community Health Workers

2 months ago talkbio0Tagged Advocacy, CHW Access Act, Community Health Workers, digital infrastructure, Health Equity, National Association of, Policy, sanofi, sustainability

Sanofi; community health workers; sustainability; health equity; National Association of Community Health Workers; policy advocacy; digital infrastructure; CHW Access Act

CDC Staff and Medical Organization Liaisons Barred from New ACIP Covid-19 Working Group

2 months ago talkbio0Tagged ACIP, Centers for Disease Control and Prevention (U.S.), COVID19 (disease), Jr., medical groups, Policy, Robert F. Kennedy, staff exclusion, Vaccines, Working Group

CDC; ACIP; Covid-19; working group; staff exclusion; medical groups barred; vaccine policy; Robert F. Kennedy Jr.

Resilience Through Reinvention: How Pharma is Navigating Uncertainty During Turbulent Times

2 months ago talkbio0Tagged adaptation, Apis (invertebrate), Clinical Trials, drug price, Generalized, Investments, manufacturing uncertainty, Market, Pharma, Policy, regulatory environment, Reinvention, resilience, strategic reserves, supply chain

pharma; resilience; reinvention; supply chain; manufacturing uncertainty; regulatory environment; global market adaptation; funding; investment; clinical trials; drug pricing policy; APIs; strategic reserves

Trump’s Most Favored Nation Policy and EU Generics: Recent Developments

2 months ago talkbio0Tagged drug price, EU, generics, Nation, Pharma, Policy, tariffs, Transplant Registry Unified Management Program

Trump; Most Favored Nation policy; EU generics; drug pricing; tariffs; pharma